Unicycive Therapeutics OLC New Drug Application Accepted by FDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 29 2026
0mins
Should l Buy UNCY?
Unicycive Therapeutics announced that the U.S. Food and Drug Administration, FDA, has accepted the resubmission of its New Drug Application, NDA, for oxylanthanum carbonate, OLC, the Company's investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease, CKD, on dialysis. The Agency has deemed the OLC resubmission to be a Class II complete response which has a six-month review period from the date of resubmission and set a Prescription Drug User Fee Act, PDUFA, target action date of June 27, 2026. "We are pleased that the agency has promptly accepted the resubmission of our NDA for OLC," said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. "We are advancing our commercial preparation activities in anticipation of a potential launch of OLC later this year, to help provide an important treatment option to patients with chronic kidney disease on dialysis who continue to struggle with hyperphosphatemia."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNCY
Wall Street analysts forecast UNCY stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.760
Low
21.00
Averages
35.80
High
60.00
Current: 6.760
Low
21.00
Averages
35.80
High
60.00
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes Inc. (NASDAQ: ASPI) and its executives' motion to dismiss, allowing the securities fraud class action to proceed, indicating significant legal exposure for the company.
- False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could have long-term financial repercussions for the firm.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, suggesting that legal proceedings may provide remedies for affected investors and enhance market confidence in corporate governance.
- Future Risk Assessment: As the lawsuit progresses, ASP Isotopes may face increased regulatory scrutiny and a crisis of market trust, impacting its future financing capabilities and business development strategies, necessitating close monitoring of subsequent developments.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The class action against ASP Isotopes (NASDAQ: ASPI) continues after the Southern District of New York partially denied the defendants' motion to dismiss, indicating potential legal liabilities for the company and its executives, which could undermine investor confidence.
- False Statement Allegations: The lawsuit alleges that the company made materially false and misleading statements regarding its uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which may have long-term implications for its financial health.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, highlighting the potential impact of legal actions on corporate governance structures.
- Market Reaction: As the lawsuit progresses, investor confidence in the company's future may wane, leading to stock price volatility, reflecting the market's heightened scrutiny of the company's transparency and compliance.
See More
Unicycive's Drug Application Accepted by FDA with Target Date Set
- FDA Acceptance: Unicycive's New Drug Application for oxylanthanum carbonate (OLC) has been accepted by the FDA, with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026, marking a significant advancement in chronic kidney disease treatment.
- Strong Financial Position: Unicycive ended 2025 with an unaudited cash position of $41.3 million, which is expected to support its OLC commercialization activities into 2027, ensuring ongoing investment in research and market launch efforts.
- Clinical Research Support: The NDA for OLC is backed by data from three clinical studies, demonstrating its potential in treating hyperphosphatemia, and the FDA raised no concerns regarding its safety or efficacy data, bolstering market confidence.
- Strong Market Demand: Hyperphosphatemia is prevalent among end-stage renal disease patients, with over 450,000 individuals annually requiring medication to control phosphate levels, and the launch of OLC will provide a crucial treatment option for this large patient population, indicating significant market potential.
See More
Unicycive's Kidney Disease Therapy NDA Accepted by FDA
- Drug Application Progress: Unicycive Therapeutics announced that the FDA has accepted its New Drug Application for oxylanthanum carbonate, marking a significant advancement in treating hyperphosphatemia in chronic kidney disease patients.
- FDA Review Timeline: The FDA has set a target action date of June 27, 2026, indicating that the resubmission is classified as a Class II complete response, which entails a six-month review period.
- Financial Position: As of the end of 2025, Unicycive reported $41.3 million in cash and short-term investments, demonstrating the company's capacity to support future drug launch activities.
- Market Outlook: The company noted that its current liquidity position could facilitate potential launch activities for OLC and extend its cash runway into 2027, enhancing its competitive stance in the market.
See More
Unicycive's Drug Application Accepted by FDA
- Drug Application Progress: Unicycive's oxylanthanum carbonate (OLC) New Drug Application has been accepted by the FDA, with a review period ending on June 27, 2026, laying the groundwork for the company's market launch among chronic kidney disease patients.
- Strong Financial Position: Unicycive ended 2025 with $41.3 million in cash and short-term investments, ensuring continued advancement of OLC's commercialization activities into 2027, thereby enhancing its competitive edge in the market.
- Clinical Research Support: The NDA for OLC is backed by data from three clinical studies and multiple preclinical studies, with the FDA raising no concerns regarding its safety or efficacy, providing robust support for the drug's approval.
- Significant Market Potential: As a novel oral phosphate binder, OLC is expected to significantly improve treatment adherence among chronic kidney disease patients, addressing the urgent needs of over 450,000 individuals in the U.S. requiring medication to control phosphate levels annually.
See More
Unicycive Resubmits NDA for OLC to Treat Hyperphosphatemia in CKD Patients
- NDA Resubmission: Unicycive Therapeutics has resubmitted its New Drug Application for oxylanthanum carbonate (OLC) to the FDA, aimed at treating hyperphosphatemia in chronic kidney disease patients on dialysis, marking a significant step in addressing previously cited deficiencies.
- Compliance Progress: The resubmission follows substantial progress by the company's original third-party manufacturing vendor in rectifying issues identified by the FDA, demonstrating the company's commitment to regulatory compliance.
- Financial Stability: CEO Shalabh Gupta noted that with a cash runway extending into 2027, the company is well-positioned to complete the regulatory process and prepare for a potential OLC launch, which enhances market confidence.
- Stock Price Increase: Following the resubmission announcement, Unicycive's shares closed at $6.07 on Friday, reflecting a 3.58% increase, indicating investor optimism regarding the company's future prospects.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes Inc. (NASDAQ: ASPI) and its executives' motion to dismiss, allowing the securities fraud class action to proceed, indicating significant legal exposure for the company.
- False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could have long-term financial repercussions for the firm.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, suggesting that legal proceedings may provide remedies for affected investors and enhance market confidence in corporate governance.
- Future Risk Assessment: As the lawsuit progresses, ASP Isotopes may face increased regulatory scrutiny and a crisis of market trust, impacting its future financing capabilities and business development strategies, necessitating close monitoring of subsequent developments.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The class action against ASP Isotopes (NASDAQ: ASPI) continues after the Southern District of New York partially denied the defendants' motion to dismiss, indicating potential legal liabilities for the company and its executives, which could undermine investor confidence.
- False Statement Allegations: The lawsuit alleges that the company made materially false and misleading statements regarding its uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which may have long-term implications for its financial health.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, highlighting the potential impact of legal actions on corporate governance structures.
- Market Reaction: As the lawsuit progresses, investor confidence in the company's future may wane, leading to stock price volatility, reflecting the market's heightened scrutiny of the company's transparency and compliance.
See More
Unicycive's Drug Application Accepted by FDA with Target Date Set
- FDA Acceptance: Unicycive's New Drug Application for oxylanthanum carbonate (OLC) has been accepted by the FDA, with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026, marking a significant advancement in chronic kidney disease treatment.
- Strong Financial Position: Unicycive ended 2025 with an unaudited cash position of $41.3 million, which is expected to support its OLC commercialization activities into 2027, ensuring ongoing investment in research and market launch efforts.
- Clinical Research Support: The NDA for OLC is backed by data from three clinical studies, demonstrating its potential in treating hyperphosphatemia, and the FDA raised no concerns regarding its safety or efficacy data, bolstering market confidence.
- Strong Market Demand: Hyperphosphatemia is prevalent among end-stage renal disease patients, with over 450,000 individuals annually requiring medication to control phosphate levels, and the launch of OLC will provide a crucial treatment option for this large patient population, indicating significant market potential.
See More
Unicycive's Kidney Disease Therapy NDA Accepted by FDA
- Drug Application Progress: Unicycive Therapeutics announced that the FDA has accepted its New Drug Application for oxylanthanum carbonate, marking a significant advancement in treating hyperphosphatemia in chronic kidney disease patients.
- FDA Review Timeline: The FDA has set a target action date of June 27, 2026, indicating that the resubmission is classified as a Class II complete response, which entails a six-month review period.
- Financial Position: As of the end of 2025, Unicycive reported $41.3 million in cash and short-term investments, demonstrating the company's capacity to support future drug launch activities.
- Market Outlook: The company noted that its current liquidity position could facilitate potential launch activities for OLC and extend its cash runway into 2027, enhancing its competitive stance in the market.
See More
Unicycive's Drug Application Accepted by FDA
- Drug Application Progress: Unicycive's oxylanthanum carbonate (OLC) New Drug Application has been accepted by the FDA, with a review period ending on June 27, 2026, laying the groundwork for the company's market launch among chronic kidney disease patients.
- Strong Financial Position: Unicycive ended 2025 with $41.3 million in cash and short-term investments, ensuring continued advancement of OLC's commercialization activities into 2027, thereby enhancing its competitive edge in the market.
- Clinical Research Support: The NDA for OLC is backed by data from three clinical studies and multiple preclinical studies, with the FDA raising no concerns regarding its safety or efficacy, providing robust support for the drug's approval.
- Significant Market Potential: As a novel oral phosphate binder, OLC is expected to significantly improve treatment adherence among chronic kidney disease patients, addressing the urgent needs of over 450,000 individuals in the U.S. requiring medication to control phosphate levels annually.
See More
Unicycive Resubmits NDA for OLC to Treat Hyperphosphatemia in CKD Patients
- NDA Resubmission: Unicycive Therapeutics has resubmitted its New Drug Application for oxylanthanum carbonate (OLC) to the FDA, aimed at treating hyperphosphatemia in chronic kidney disease patients on dialysis, marking a significant step in addressing previously cited deficiencies.
- Compliance Progress: The resubmission follows substantial progress by the company's original third-party manufacturing vendor in rectifying issues identified by the FDA, demonstrating the company's commitment to regulatory compliance.
- Financial Stability: CEO Shalabh Gupta noted that with a cash runway extending into 2027, the company is well-positioned to complete the regulatory process and prepare for a potential OLC launch, which enhances market confidence.
- Stock Price Increase: Following the resubmission announcement, Unicycive's shares closed at $6.07 on Friday, reflecting a 3.58% increase, indicating investor optimism regarding the company's future prospects.
See More
